欧洲心力衰竭利钠肽检测实践现状:CARMAGUE研究
欧洲临床化学与实验室医学联合会(EFLM)于2019年通过欧洲各国生化协会向临床实验室发放网络问卷,调查心力衰竭(HF)生物标志物检测是否符合更新后的指南。347家实验室参与,其中266家开展利钠肽(NP)检测;2013至2019年间NP检测率由67%升至77%,NT-proBNP仍为首选标志物。BNP推荐决策限落实率85%,NT-proBNP针对性设置比例为40%,优于既往调查;检验人员愿意支持按年龄、性别及肾功能不全等情况调整cut-off值。
要点
- 2013至2019年欧洲实验室NP检测率由67%升至77%,NT-proBNP仍为首选标志物。
- BNP推荐决策限落实率为85%,NT-proBNP针对性设置决策限的比例为40%。
- 检验人员愿意支持按年龄、性别及肾功能不全等条件调整cut-off值。
核心结论
- 指南推动临床实验室开展对HF诊断与管理有高价值的NP检测,并给出经调整的医学决策限。
- 未来指南应鼓励针对部分混杂因素使用个体化cut-off值。
研究设计与样本
- EFLM发起的CARMAGUE研究,为基于网络的问卷调查,2019年经欧洲各国生化协会发放至临床实验室。
- 共347家实验室参与,多数来自欧洲国家,其中266家开展NP检测;问卷涵盖NP检测类型、HF决策限及对肾功能衰竭或肥胖患者需不同阈值的看法。
主要发现
- NP检测率由2013年的67%升至2019年的77%,NT-proBNP仍为首选生物标志物。
- BNP推荐决策限落实率为85%,NT-proBNP针对性设置决策限的比例为40%,优于既往调查。
- 调查显示检验人员愿意支持将按年龄、性别及肾功能不全等状况调整的cut-off值转化为实际应用。
关键数值与推荐
- NP检测率:2013年67%,2019年77%。
- BNP推荐决策限落实率85%;NT-proBNP针对性设置决策限比例40%。
- 参与实验室347家,开展NP检测者266家。
临床怎么用
- 检验科应依据更新指南开展NP检测并设置推荐的医学决策限,助力HF诊断与管理。
- 可结合年龄、性别及肾功能不全等混杂因素探索个体化cut-off值的报告与应用。
局限性
- 为2019年发放的网络问卷调查,结果基于参与实验室的自报信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to survey if current biomarker testing for heart failure (HF) in Europe is in accordance with up-dated guidelines. METHODS: A web-based questionnaire was distributed to clinical laboratories via European biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP) assays performed, decision limits for HF, and opinion concerning requirement of different thresholds in patients with renal failure or obesity. RESULTS: There were 347 participating laboratories mostly from European countries with 266 offering NP testing. NP testing was increased from 67% to 77% between 2013 and 2019. NT-proBNP remained the preferred biomarker. Recommended decision limits were implemented for BNP (85%) and better focused for NT-proBNP (40%) than in the previous survey. The survey revealed that laboratorians are willing to support the translation of adjusted cut-off values for age, gender and for patients with conditions like renal insufficiency. CONCLUSION: Guidelines stimulate clinical laboratories to offer NP testing with high value for the diagnosis and management of HF, and to present adjusted medical decision limits. Future guidelines should encourage the use of personalized cut-offs for some confounding factors.
引用
- Hammerer-Lercher A, Gruson D, Stankovic S, et al. Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MArker guideline Uptake in Europe (CARMAGUE) study. Clin Chim Acta. 2020. PMID: 33002472. doi:10.1016/j.cca.2020.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。